-
Study: Lemtrada Sustains Long-Term Benefits for RRMS Patients
Earlier this month, researchers presented key findings about the MS drug Lemtrada at the 2018 Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles. The presentations covered two pivotal clinical trials of Lemtrada in which annualized relapse rates remained low; an increased number of patients experienced confirmed improvements in disability; and fewer MS patients reported their disability worsening.
You can read a detailed summary of the findings at Multiple Sclerosis News Today: “#AAN2018 — Lemtrada Sustains Long-Term Benefits for RRMS Patients, TOPAZ Study Shows”
Have you heard of or tried Lemtrada? Has it helped you? What do you think about the serious side effects that can accompany MS treatments?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.